India’s science-backed skincare boom draws fresh investor attention as dermocosmetics segment expands

India’s skincare industry is increasingly moving away from mass-market beauty positioning toward clinically validated, dermatology-led products, reflecting a broader global shift in consumer health and wellness spending. Across Asia-Pacific markets, consumers are showing growing preference for science-backed skincare formulations tailored to local skin conditions, climate, and pigmentation profiles. The global dermocosmetics market — a category sitting at the intersection of pharmaceuticals and cosmetics — is projected to cross USD 100 billion over the next few years, driven by rising awareness around skin health, preventive aging, and ingredient transparency.

In India, the premium skincare segment has grown rapidly after the pandemic, aided by digital commerce, social media education, and increasing consultations with dermatologists. Industry estimates suggest India’s beauty and personal care market could exceed USD 30 billion by the end of the decade, with dermaceutical and clinically positioned skincare among the fastest-growing categories. Venture capital firms, which once focused primarily on direct-to-consumer beauty brands built around marketing-led growth, are now showing stronger interest in companies backed by scientific research, proprietary formulations, and medical credibility.

Against this backdrop, Chennai-based CHOSEN, which positions itself as India’s first exposome-based skincare brand, has secured fresh institutional capital to expand its research capabilities and product portfolio. The investment reflects a broader investor appetite for healthcare-adjacent consumer brands that combine clinical validation with scalable consumer distribution.

CHOSEN secures USD 5 million Series A funding led by Fireside Ventures

CHOSEN has raised USD 5 million in a Series A funding round led by Fireside Ventures, with participation from BOLD, L’Oréal’s corporate venture capital fund and Alkemi Growth Capital. The round also included angel investor Avnish Anand, alongside a group of practicing dermatologists including Dr Chandan Asokan, Dr KC Nischal, Dr Punit Saraogi, Dr Nishita Ranka, and Dr Mikki Singh.

The company did not disclose its valuation following the funding round. CHOSEN was founded in 2020 by cosmetic dermatologist Dr Renita Rajan and has focused on building products specifically designed for melanin-rich Indian skin.

The fresh capital will primarily be used to strengthen the company’s research and development capabilities, expand its product pipeline, scale its dermatologist-led Centre of Excellence, and hire talent across research, product development, and operational functions.

CHOSEN’s positioning is built around the concept of the “exposome” — a scientific framework studying the cumulative environmental factors that influence skin aging and health. The company says its formulations are designed around four major domains affecting Indian skin: pigmentation, texture, contour, and hair aging.

For investors, the company represents a relatively differentiated bet within India’s crowded beauty startup ecosystem. Instead of relying primarily on influencer-led marketing or fast-moving beauty trends, CHOSEN has built its identity around clinical research and dermatologist participation. That approach appears to have resonated with institutional investors increasingly searching for defensible consumer-health brands.

In a statement, Dr Renita Rajan said Indian dermatology expertise had historically contributed significantly to therapeutic medicine, while skincare and personal care products often continued to rely on imported frameworks that were not specifically designed for Indian skin and climate conditions.

Fireside Ventures, known for backing consumer brands across food, wellness, and personal care, said CHOSEN’s clinical credibility and repeat consumer behavior stood out. The investment firm also highlighted the company’s access to dermatological clinical data and its capital-efficient growth approach.

The participation of BOLD, the venture investment arm of L’Oréal Groupe, also signals rising global interest in India’s premium skincare ecosystem. Global beauty conglomerates are increasingly looking toward India not just as a consumer market but also as a source of innovation tailored for skin of colour and tropical climate conditions.

CHOSEN bets on clinical skincare model built around Indian skin conditions

CHOSEN operates at the intersection of dermatology, skincare, and nutraceuticals, following what it describes as a clinic-to-consumer business model. Unlike traditional cosmetic brands that depend heavily on mass retail distribution and celebrity-driven branding, the company has built much of its early growth through dermatologist recommendations and protocol-based skincare systems.

Its revenue model combines direct-to-consumer sales, dermatologist-led prescriptions, and repeat purchase cycles for long-term skincare regimens. Products are sold online while also leveraging networks of skin clinics and medical practitioners. This structure gives the company access to medically informed consumer acquisition channels that many beauty startups struggle to replicate.

The company’s portfolio includes topical formulations as well as ingestible nutraceutical products targeting anti-aging and skin health. Its flagship products include SAFESCREEN® NEXGEN sunscreen and the CHOSEN Sculpt protocol, a topical contour system designed specifically for Indian women.

One of CHOSEN’s central differentiators is its focus on melanin-rich skin, a segment historically underserved by global skincare formulations that were often designed primarily for Western skin types and climatic conditions. Skin pigmentation patterns, UV exposure intensity, humidity, pollution levels, and environmental stressors differ significantly across geographies, creating demand for localized dermatological solutions.

The company also emphasizes evidence-based product development, an increasingly important factor among urban Indian consumers. As skincare literacy rises, buyers are paying closer attention to ingredient efficacy, clinical testing, and dermatologist endorsements rather than relying solely on beauty branding.

CHOSEN’s “exposome” positioning further reflects a broader global movement in skincare research. Internationally, skincare companies are increasingly studying the combined impact of pollution, ultraviolet radiation, stress, sleep, and diet on skin aging. This creates opportunities for companies capable of combining dermatological science with consumer-friendly products.

Another important aspect of CHOSEN’s business model is its relatively capital-efficient growth strategy. Investor statements suggest the company has focused on high repeat rates and structured treatment protocols rather than spending aggressively on customer acquisition. In India’s current funding environment — where investors have become more cautious about burn-heavy consumer startups — profitability pathways and operational discipline are receiving greater attention.

The company’s emphasis on a dermatologist-led Centre of Excellence may also help it create a stronger moat through clinical validation and proprietary data generation. If scaled effectively, such infrastructure could become a meaningful competitive advantage in a sector where product differentiation is often difficult to sustain.

Competition intensifies in India’s dermatology-led skincare segment

CHOSEN operates in an increasingly competitive skincare market where multiple startups and established global brands are racing to capture premium consumers seeking medically positioned products.

In India, companies such as Minimalist, The Derma Co, and SkinQ have helped popularize ingredient-led and science-focused skincare. These brands have gained traction through transparency around active ingredients and digital-first marketing strategies.

However, CHOSEN’s approach differs in its stronger emphasis on dermatologist participation and clinical protocols. Rather than functioning primarily as a beauty ecommerce brand, the company positions itself closer to a dermaceutical platform grounded in medical expertise.

Globally, the dermocosmetics category is dominated by multinational companies including La Roche-Posay, CeraVe, and SkinCeuticals, many of which have deep research budgets and established relationships with dermatologists. European markets, particularly France, have historically led the dermocosmetics category due to the strong overlap between pharmacy retail and skincare.

The US market, meanwhile, has seen rapid growth in physician-backed skincare and longevity-focused beauty products, especially among affluent consumers willing to pay premium prices for clinically validated formulations.

India’s market remains comparatively early-stage but is growing rapidly due to rising disposable incomes, social media-driven skincare awareness, and expanding urban wellness spending. What differentiates the Indian market is the need for products tailored to darker skin tones, tropical climate exposure, and local environmental conditions — areas where domestic companies may hold an advantage over imported global brands.

The entrance of global strategic investors into Indian skincare startups also suggests that multinational beauty companies are closely monitoring regional innovation ecosystems for future partnerships, acquisitions, or distribution opportunities.

Funding reflects broader shift toward science-backed consumer health brands

CHOSEN’s funding round highlights a broader shift underway in venture capital allocation across India’s consumer sector. Investors are increasingly moving away from businesses driven purely by branding and discount-led customer acquisition toward companies with stronger intellectual property, clinical positioning, and repeat consumer behavior.

This transition is visible across wellness, nutrition, preventive healthcare, and skincare categories, where the boundaries between medical science and consumer products are increasingly overlapping. The rise of dermaceuticals mirrors similar trends in functional nutrition and digital health, where consumers are willing to pay premium prices for products positioned around measurable outcomes and scientific credibility.

The participation of corporate venture capital funds such as BOLD also signals rising strategic interest from global beauty companies seeking exposure to localized innovation. India’s beauty market has become one of the fastest-growing globally, but consumer preferences increasingly require region-specific solutions rather than standardized international products.

For the broader economy, such investments indicate growing confidence in India’s ability to build specialized consumer-health brands with export potential. As Indian startups move beyond generic direct-to-consumer models, investors appear more willing to support companies with deeper research capabilities and differentiated positioning.

The funding environment for consumer startups has become more selective over the past two years amid tighter global liquidity conditions and pressure on valuations. In that context, CHOSEN’s ability to attract institutional investors suggests that healthcare-adjacent consumer brands may continue to command investor attention even as broader venture funding remains cautious.

The deal also reflects another emerging trend: increasing participation of domain experts and practitioners in startup funding rounds. The inclusion of dermatologists as investors strengthens CHOSEN’s medical positioning while potentially helping expand practitioner adoption and trust networks.

As India’s skincare market matures, companies able to combine clinical validation, localized product development, and sustainable customer retention are likely to become increasingly attractive to both financial and strategic investors.